Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


H1N1 Infection-Pipeline Review, H1 2015

H1N1 Infection-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

H1N1 Infection-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'H1N1 Infection-Pipeline Review, H1 2015', provides an overview of the H1N1 Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of H1N1 Infection

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for H1N1 Infection and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the H1N1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the H1N1 Infection pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for H1N1 Infection

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

H1N1 Infection Overview 8

Therapeutics Development 9

Pipeline Products for H1N1 Infection-Overview 9

Pipeline Products for H1N1 Infection-Comparative Analysis 10

H1N1 Infection-Therapeutics under Development by Companies 11

H1N1 Infection-Therapeutics under Investigation by Universities/Institutes 15

H1N1 Infection-Pipeline Products Glance 17

Clinical Stage Products 17

Early Stage Products 18

H1N1 Infection-Products under Development by Companies 19

H1N1 Infection-Products under Investigation by Universities/Institutes 22

H1N1 Infection-Companies Involved in Therapeutics Development 23

Adamas Pharmaceuticals, Inc. 23

Akshaya Bio Inc. 24

AlphaVax, Inc. 25

Antigen Express, Inc. 26

Beijing Minhai Biotechnology Co., Ltd 27

Bionor Pharma ASA 28

CEL-SCI Corporation 29

Cilian AG 30

Colby Pharmaceutical Company 31

Crucell N.V. 32

EpiVax, Inc. 33

Etubics Corporation 34

Gemmus Pharma Inc. 35

iBio, Inc. 36

Inovio Pharmaceuticals, Inc. 37

Johnson & Johnson 38

Kineta, Inc. 39

Kyowa Hakko Kirin Co., Ltd. 40

Medicago Inc. 41

NanoViricides, Inc. 42

Onxeo SA 43

OPKO Health, Inc. 44

REPLICor Inc. 45

Revivicor, Inc. 46

Sarepta Therapeutics, Inc. 47

Sirnaomics, Inc. 48

TaiMed Biologics Inc. 49

Takeda Pharmaceutical Company Limited 50

TechnoVax, Inc. 51

Vaxart, Inc. 52

Vaxin, Inc. 53

Vaxine Pty Ltd 54

H1N1 Infection-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Combination Products 56

Assessment by Target 57

Assessment by Mechanism of Action 59

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

ADS-324-Drug Profile 65

AEA-35p-Drug Profile 66

Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza-Drug Profile 67

Aspidasept-Drug Profile 68

BA-032-Drug Profile 69

C-05-Drug Profile 70

CiFlu-Drug Profile 71

CR-9114-Drug Profile 73

CYM-5442-Drug Profile 74

diridavumab-Drug Profile 75

FVH-1-Drug Profile 77

Gamma-Flu-Drug Profile 78

GP-1001-Drug Profile 79

GP-1681-Drug Profile 80

GREFLU/CAL-Drug Profile 82

H1N1 [A/Aichi/2/68] vaccine-Drug Profile 83

Human Antibody Based Vaccines-Drug Profile 84

Influ-nRNA-Drug Profile 86

influenza (strain H5N1, H1N1) vaccine-Drug Profile 87

influenza [H1N1] (quadrivalent) virus like particle vaccine-Drug Profile 88

influenza [H1N1] vaccine-Drug Profile 90

influenza [strain A/H1N1] vaccine-Drug Profile 91

influenza [strain H1N1] (mutivalent) vaccine-Drug Profile 92

influenza [strain H1N1] vaccine-Drug Profile 93

influenza A vaccine-Drug Profile 94

influenza vaccine-Drug Profile 95

influenza vaccine-Drug Profile 96

influenza vaccine-Drug Profile 98

influenza vaccine [H1N1]-Drug Profile 99

Innate Immune Agonists-Drug Profile 101

INO-3401-Drug Profile 102

INO-3510-Drug Profile 103

INO-3605-Drug Profile 104

INO-3609-Drug Profile 105

JVRS-100 + influenza [H1N1/H3N2] vaccine-Drug Profile 106

LEAPS-H1N1-DC-Drug Profile 107

NVINF-1-Drug Profile 108

NVINF-2-Drug Profile 110

pandemic influenza [H1N1] (monovalent) vaccine-Drug Profile 111

pandemic influenza [H5N1/H1N1] vaccine-Drug Profile 112

pandemic influenza vaccine [H1N1]-Drug Profile 113

radavirsen-Drug Profile 114

REP-9-Drug Profile 116

RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection-Drug Profile 117

Small Molecules to Block M2 Channel for Influenza Infections-Drug Profile 118

STP-702-Drug Profile 119

Synthetic Peptides for Influenza, HSV and HIV Infections-Drug Profile 120

TMB-571-Drug Profile 121

TVX-002-Drug Profile 122

Vacc-Flu-Drug Profile 123

Vaccine to Target TLR2 for Infectious Disease-Drug Profile 124

VH-244-Drug Profile 125

VX-787-Drug Profile 127

VXAA-1.1-Drug Profile 128

Z-3G1-Drug Profile 129

H1N1 Infection-Recent Pipeline Updates 130

H1N1 Infection-Dormant Projects 143

H1N1 Infection-Product Development Milestones 146

Featured News & Press Releases 146

Appendix 156

Methodology 156

Coverage 156

Secondary Research 156

Primary Research 156

Expert Panel Validation 156

Contact Us 156

Disclaimer 157

List of Tables

Number of Products under Development for H1N1 Infection, H1 2015 13

Number of Products under Development for H1N1 Infection-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

H1N1 Infection-Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 27

H1N1 Infection-Pipeline by Akshaya Bio Inc., H1 2015 28

H1N1 Infection-Pipeline by AlphaVax, Inc., H1 2015 29

H1N1 Infection-Pipeline by Antigen Express, Inc., H1 2015 30

H1N1 Infection-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 31

H1N1 Infection-Pipeline by Bionor Pharma ASA, H1 2015 32

H1N1 Infection-Pipeline by CEL-SCI Corporation, H1 2015 33

H1N1 Infection-Pipeline by Cilian AG, H1 2015 34

H1N1 Infection-Pipeline by Colby Pharmaceutical Company, H1 2015 35

H1N1 Infection-Pipeline by Crucell N.V., H1 2015 36

H1N1 Infection-Pipeline by EpiVax, Inc., H1 2015 37

H1N1 Infection-Pipeline by Etubics Corporation, H1 2015 38

H1N1 Infection-Pipeline by Gemmus Pharma Inc., H1 2015 39

H1N1 Infection-Pipeline by iBio, Inc., H1 2015 40

H1N1 Infection-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 41

H1N1 Infection-Pipeline by Johnson & Johnson, H1 2015 42

H1N1 Infection-Pipeline by Kineta, Inc., H1 2015 43

H1N1 Infection-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 44

H1N1 Infection-Pipeline by Medicago Inc., H1 2015 45

H1N1 Infection-Pipeline by NanoViricides, Inc., H1 2015 46

H1N1 Infection-Pipeline by Onxeo SA, H1 2015 47

H1N1 Infection-Pipeline by OPKO Health, Inc., H1 2015 48

H1N1 Infection-Pipeline by REPLICor Inc., H1 2015 49

H1N1 Infection-Pipeline by Revivicor, Inc., H1 2015 50

H1N1 Infection-Pipeline by Sarepta Therapeutics, Inc., H1 2015 51

H1N1 Infection-Pipeline by Sirnaomics, Inc., H1 2015 52

H1N1 Infection-Pipeline by TaiMed Biologics Inc., H1 2015 53

H1N1 Infection-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 54

H1N1 Infection-Pipeline by TechnoVax, Inc., H1 2015 55

H1N1 Infection-Pipeline by Vaxart, Inc., H1 2015 56

H1N1 Infection-Pipeline by Vaxin, Inc., H1 2015 57

H1N1 Infection-Pipeline by Vaxine Pty Ltd, H1 2015 58

Assessment by Monotherapy Products, H1 2015 59

Assessment by Combination Products, H1 2015 60

Number of Products by Stage and Target, H1 2015 62

Number of Products by Stage and Mechanism of Action, H1 2015 64

Number of Products by Stage and Route of Administration, H1 2015 66

Number of Products by Stage and Molecule Type, H1 2015 68

H1N1 Infection Therapeutics-Recent Pipeline Updates, H1 2015 134

H1N1 Infection-Dormant Projects, H1 2015 147

H1N1 Infection-Dormant Projects (Contd..1), H1 2015 148

H1N1 Infection-Dormant Projects (Contd..2), H1 2015 149

List of Figures

Number of Products under Development for H1N1 Infection, H1 2015 13

Number of Products under Development for H1N1 Infection-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 59

Number of Products by Top 10 Targets, H1 2015 61

Number of Products by Stage and Top 10 Targets, H1 2015 61

Number of Products by Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Top 10 Routes of Administration, H1 2015 65

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 66

Number of Products by Top 10 Molecule Types, H1 2015 67

Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adamas Pharmaceuticals, Inc.

Akshaya Bio Inc.

AlphaVax, Inc.

Antigen Express, Inc.

Beijing Minhai Biotechnology Co., Ltd

Bionor Pharma ASA

CEL-SCI Corporation

Cilian AG

Colby Pharmaceutical Company

Crucell N.V.

EpiVax, Inc.

Etubics Corporation

Gemmus Pharma Inc.

iBio, Inc.

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Kineta, Inc.

Kyowa Hakko Kirin Co., Ltd.

Medicago Inc.

NanoViricides, Inc.

Onxeo SA

OPKO Health, Inc.

REPLICor Inc.

Revivicor, Inc.

Sarepta Therapeutics, Inc.

Sirnaomics, Inc.

TaiMed Biologics Inc.

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

Vaxart, Inc.

Vaxin, Inc.

Vaxine Pty Ltd

H1N1 Infection Therapeutic Products under Development, Key Players in H1N1 Infection Therapeutics, H1N1 Infection Pipeline Overview, H1N1 Infection Pipeline, H1N1 Infection Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com